It’s only fair to share… Lixosicone CAS 1610878-71-1 MF C29H40O3 MW 436.6 g/mol 1-[(3S,8S,9S,10R,13S,14S,17S)-3-[(4-methoxyphenyl)methoxy]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone 3β-[(4-methoxyphenyl)methoxy]pregn-5-en-20-onecannabinoid CB1 receptor signalling inhibitor, AEF0117, AEF 0117, 9LG9CT78SV AEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects). Lixosicone (AEF0117, 3β-(4-methoxybenzyloxy)pregn-5-en-20-one) is a compound derived from pregnenolone by …